Last reviewed · How we verify
Ticagrelor monotherapy
Ticagrelor monotherapy is a Small molecule drug developed by Yonsei University. It is currently FDA-approved. Also known as: Brilinta®, Brilinta, Study group.
Ticagrelor is a small molecule that acts as a negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor. It is used in the treatment of conditions such as coronary artery disease, CABG, and thrombosis, often in combination with other antiplatelet therapies like aspirin and clopidogrel.
At a glance
| Generic name | Ticagrelor monotherapy |
|---|---|
| Also known as | Brilinta®, Brilinta, Study group |
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ticagrelor Monotherapy After Stenting (PHASE2)
- The 10-Year Extended Follow-up of the DACAB Trial
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (NA)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors (PHASE4)
- Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor monotherapy CI brief — competitive landscape report
- Ticagrelor monotherapy updates RSS · CI watch RSS
- Yonsei University portfolio CI
Frequently asked questions about Ticagrelor monotherapy
What is Ticagrelor monotherapy?
Who makes Ticagrelor monotherapy?
Is Ticagrelor monotherapy also known as anything else?
What development phase is Ticagrelor monotherapy in?
Related
- Manufacturer: Yonsei University — full pipeline
- Also known as: Brilinta®, Brilinta, Study group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing